Growth Metrics

Emergent BioSolutions (EBS) Accounts Payables (2016 - 2025)

Emergent BioSolutions' Accounts Payables history spans 16 years, with the latest figure at $55.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 8.7% year-over-year to $55.6 million; the TTM value through Dec 2025 reached $55.6 million, down 8.7%, while the annual FY2025 figure was $55.6 million, 8.7% down from the prior year.
  • Accounts Payables reached $55.6 million in Q4 2025 per EBS's latest filing, down from $57.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $151.8 million in Q2 2021 to a low of $55.6 million in Q4 2025.
  • Average Accounts Payables over 5 years is $100.4 million, with a median of $104.8 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: skyrocketed 79.01% in 2021, then tumbled 45.72% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $128.9 million in 2021, then dropped by 19.71% to $103.5 million in 2022, then grew by 8.41% to $112.2 million in 2023, then tumbled by 45.72% to $60.9 million in 2024, then dropped by 8.7% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Accounts Payables are $55.6 million (Q4 2025), $57.4 million (Q3 2025), and $63.7 million (Q2 2025).